Biotechnology California, USA-based rare disease company Reneo Pharmaceuticals saw its shares fall 12.2% to $1.59 yesterday, when it announced it has entered into a definitive merger agreement with privately-held OnKure to combine the companies in an all-stock transaction. 14 May 2024